Biomarkers

Discover all biomarkers in precision medicine

Loading biomarkers...

Vascular Endothelial Growth Factor - Biomarker

Results for "Vascular endothelial growth factor C"

Target: Vascular endothelial growth factor C

Growth factor active in angiogenesis, and endothelial cell growth, stimulating their proliferation and migration and also has effects on the permeability of blood vessels. May function in angiogenesis of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Binds and activates KDR/VEGFR2 and FLT4/VEGFR3 receptors

Clinical Applications

Breast CancerAcute Kidney InjuryNormalPOEMS

Status: approved

APPROVED

Pipeline Therapies

FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer

City of Hope Medical Center

PHASE1, PHASE2

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

PHASE1

Improving Cerebral Blood Flow and Cognition in Patients with Cerebral Small Vessel Disease. the ETLAS-2 Trial

Herlev Hospital

PHASE2

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

PHASE2

PRO-VISION: Patient Reported Outcomes-Based Monitoring of VEGF-Inhibitor Side Effects in ONcology

UNC Lineberger Comprehensive Cancer Center

Companies Working on Vascular endothelial growth factor C

City of Hope Medical Center

Metastatic Colon Adenocarcinoma

Calcium, DietaryLeucovorinFolic Acid

M.D. Anderson Cancer Center

Advanced Malignant Neoplasm

SirolimusBevacizumabAntineoplastic Agents, Immunological

Herlev Hospital

Cerebral Small Vessel Diseases

Tadalafil

National Cancer Institute (NCI)

Endometrial Adenocarcinoma

SirolimusPaclitaxelEpothilones

TrialsMap

Clinical Intelligence Agent

Interactive Clinical Trials Map

2200

United States

369

Europe

245

Asia

147

Other

LitSearch

Scientific Literature Agent

Scientific Publications

Vascular Endothelial Growth Factor Therapy for the Kidney: Are We There Yet?

PubMedJan 2016

The role of vascular endothelial growth factor in ischemic stroke.

PubMedApr 2021

Aortic dissection induced by vascular endothelial growth factor inhibitors.

PubMedNone 2023

Novel Target for Limiting VEGF-A (Vascular Endothelial Growth Factor A)-Induced Vascular Permeability.

PubMedOct 2022

Vascular endothelial growth factor.

PubMedDec 1996

Research Insights

Publication count:

5 papers

Research focus:

Breast Cancer

Sources & References

Vascular Endothelial Growth Factor Therapy for the Kidney: Are We There Yet?

PubMed•Jan 2016

The role of vascular endothelial growth factor in ischemic stroke.

PubMed•Apr 2021

Aortic dissection induced by vascular endothelial growth factor inhibitors.

PubMed•None 2023

Novel Target for Limiting VEGF-A (Vascular Endothelial Growth Factor A)-Induced Vascular Permeability.

PubMed•Oct 2022

Vascular endothelial growth factor.

PubMed•Dec 1996

Biomarkers

Results for "Vascular endothelial growth factor C"

Target: Vascular endothelial growth factor C

Clinical Applications

Approved Therapies

VABYSMO (FARICIMAB) [5]

MVASI (BEVACIZUMAB-AWWB) [6]

WELIREG (BELZUTIFAN) [7]

Opuviz (AFLIBERCEPT-YSZY) [8]

AHZANTIVE (AFLIBERCEPT-MRBB) [9]

CIMERLI (RANIBIZUMAB-EQRN) [10]

Vegzelma (BEVACIZUMAB-ADCD) [11]

BEOVU (BROLUCIZUMAB) [12]

ALYMSYS (BEVACIZUMAB-MALY) [13]

JOBEVNE (BEVACIZUMAB-NWGD) [14]

Pipeline Therapies

FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

Improving Cerebral Blood Flow and Cognition in Patients with Cerebral Small Vessel Disease. the ETLAS-2 Trial

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

PRO-VISION: Patient Reported Outcomes-Based Monitoring of VEGF-Inhibitor Side Effects in ONcology

Companies Working on Vascular endothelial growth factor C

City of Hope Medical Center

M.D. Anderson Cancer Center

Herlev Hospital

National Cancer Institute (NCI)

TrialsMap

Interactive Clinical Trials Map

LitSearch

Scientific Publications

Vascular Endothelial Growth Factor Therapy for the Kidney: Are We There Yet?

The role of vascular endothelial growth factor in ischemic stroke.

Aortic dissection induced by vascular endothelial growth factor inhibitors.

Novel Target for Limiting VEGF-A (Vascular Endothelial Growth Factor A)-Induced Vascular Permeability.

Vascular endothelial growth factor.

Research Insights

Sources & References

VABYSMO (FARICIMAB) ^[5]

MVASI (BEVACIZUMAB-AWWB) ^[6]

WELIREG (BELZUTIFAN) ^[7]

Opuviz (AFLIBERCEPT-YSZY) ^[8]

AHZANTIVE (AFLIBERCEPT-MRBB) ^[9]

CIMERLI (RANIBIZUMAB-EQRN) ^[10]

Vegzelma (BEVACIZUMAB-ADCD) ^[11]

BEOVU (BROLUCIZUMAB) ^[12]

ALYMSYS (BEVACIZUMAB-MALY) ^[13]

JOBEVNE (BEVACIZUMAB-NWGD) ^[14]